Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus Erythematosus

Autor: Christine Maric, Babbette B Lamarca, Marcia Venegas-Pont, Lorraine C. Racusen, Porter H. Glover, Michael J. Ryan, Allison V. Jones, Michaele B. Manigrasso, Samira C. Grifoni, Heather A. Drummond
Rok vydání: 2010
Předmět:
medicine.medical_specialty
Kidney Cortex
Renal cortex
Antigens
Differentiation
Myelomonocytic
Blood Pressure
Mice
Inbred Strains
Kidney
Receptors
Tumor Necrosis Factor
Article
Etanercept
Mice
chemistry.chemical_compound
Antigens
CD
immune system diseases
Internal medicine
Internal Medicine
medicine
Albuminuria
Animals
Lupus Erythematosus
Systemic
skin and connective tissue diseases
Chemokine CCL2
Creatinine
Lupus erythematosus
Endothelin-1
Glomerulosclerosis
Focal Segmental
Tumor Necrosis Factor-alpha
business.industry
Anti-Inflammatory Agents
Non-Steroidal
Body Weight
NF-kappa B
NADPH Oxidases
Glomerulosclerosis
Kidney metabolism
medicine.disease
Disease Models
Animal
medicine.anatomical_structure
Blood pressure
Endocrinology
chemistry
Immunoglobulin G
Hypertension
Female
Tumor necrosis factor alpha
business
Zdroj: Hypertension. 56:643-649
ISSN: 1524-4563
0194-911X
DOI: 10.1161/hypertensionaha.110.157685
Popis: Chronic inflammation has been implicated in the pathology of hypertension; however, the role for specific cytokines remains unclear. We tested whether tumor necrosis factor-α blockade with etanercept (Etan) reduces mean arterial pressure in a female mouse model of systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disorder with prevalent hypertension. Thirty-week–old SLE (NZBWF1) and control mice (NZW/LacJ) received Etan (0.8 mg/kg SC weekly) for 4 weeks or vehicle. Mean arterial pressure (in millimeters of mercury) was increased in SLE mice (150±5 versus 113±5 in controls; P P P + cell staining (in percentage of area) was elevated in SLE mice (4.75±0.80 versus 0.79±0.12 in controls; P P
Databáze: OpenAIRE
Externí odkaz: